Wall Street Zen Upgrades Bright Minds Biosciences (NASDAQ:DRUG) to Hold

Key Points

• Wall Street Zen upgraded Bright Minds Biosciences from “Sell” to “Hold,” while the broader analyst consensus remains “Buy,” with one Strong Buy, seven Buy and one Hold rating and an average price target of $143.83.
• Bright Minds shares opened at $77.42, with a market capitalization of approximately $753 million and a 52-week range of $38.00 to $123.75. The company remains unprofitable but exceeded quarterly loss expectations, reporting an adjusted loss of $0.17 per share versus the $1.22 consensus loss.
• Institutional ownership stands at 40.52%, with several hedge funds increasing or initiating positions. Analysts have generally narrowed projected losses through 2029 and continue to expect profitability by fiscal 2030, though the company’s outlook remains dependent on its clinical-stage drug pipeline.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.

DRUG has been the topic of a number of other research reports. Zacks Research upgraded shares of Bright Minds Biosciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 21st. BTIG Research reaffirmed a "buy" rating and issued a $147.00 target price on shares of Bright Minds Biosciences in a research report on Monday, August 17th. Piper Sandler reiterated an "overweight" rating and set a $220.00 target price (up from $190.00) on shares of Bright Minds Biosciences in a research note on Wednesday, May 20th. Benchmark reissued a "buy" rating on shares of Bright Minds Biosciences in a report on Thursday. Finally, HC Wainwright reissued a "buy" rating and set a $145.00 price target on shares of Bright Minds Biosciences in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $143.83.

Bright Minds Biosciences Stock Down 1.5%

NASDAQ:DRUG opened at $77.42 on Friday. The company's 50 day moving average price is $72.44 and its 200-day moving average price is $77.11. Bright Minds Biosciences has a 52 week low of $38.00 and a 52 week high of $123.75. The stock has a market cap of $753.45 million, a price-to-earnings ratio of -37.22 and a beta of -5.27.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last announced its quarterly earnings data on Monday, August 17th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($1.22) by $1.05. As a group, sell-side analysts anticipate that Bright Minds Biosciences will post -2.93 earnings per share for the current year.

Institutional Trading of Bright Minds Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vivo Capital LLC grew its position in shares of Bright Minds Biosciences by 99.4% during the 3rd quarter. Vivo Capital LLC now owns 501,617 shares of the company's stock valued at $30,428,000 after acquiring an additional 250,045 shares during the period. MPM Bioimpact LLC bought a new position in Bright Minds Biosciences in the 4th quarter worth $17,961,000. Balyasny Asset Management L.P. bought a new position in Bright Minds Biosciences in the 3rd quarter worth $11,339,000. Millennium Management LLC lifted its position in Bright Minds Biosciences by 376.9% during the first quarter. Millennium Management LLC now owns 192,557 shares of the company's stock valued at $6,946,000 after purchasing an additional 152,178 shares in the last quarter. Finally, Ikarian Capital LLC lifted its position in Bright Minds Biosciences by 933.1% during the fourth quarter. Ikarian Capital LLC now owns 159,421 shares of the company's stock valued at $12,441,000 after purchasing an additional 143,990 shares in the last quarter. 40.52% of the stock is owned by hedge funds and other institutional investors.

Key Bright Minds Biosciences News

Here are the key news stories impacting Bright Minds Biosciences this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for fiscal 2026 and each quarter of fiscal 2027. The firm now projects a fiscal 2026 loss of $3.15 per share, compared with its prior estimate of a $5.92 loss, and a fiscal 2027 loss of $5.83 per share versus a previous $9.07 loss. These revisions indicate expectations for slower losses and improving financial performance.
• Positive Sentiment: The analyst also improved its fiscal 2028 and fiscal 2029 forecasts, narrowing projected losses to $5.04 and $2.79 per share, respectively, from $7.93 and $4.04. The model continues to forecast a return to profitability in fiscal 2030, with projected EPS of $2.41.
• Neutral Sentiment: Despite the improved outlook, Bright Minds remains unprofitable, with a current-year consensus estimate of a $3.85-per-share loss. The company’s valuation therefore remains highly dependent on the progress and commercial potential of its drug-development pipeline.
• Negative Sentiment: HC Wainwright reduced its fiscal 2030 EPS estimate to $2.41 from $3.09, signaling some moderation in its long-term profitability assumptions. However, the firm retained its Buy rating and $145 target.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source